The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy-Reference-Cited by-同舟云学术

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

Published:2019-09-24 Issue:2 Volume:16 Page:327-334
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Volpi Antonio¹,Boccalini Sara²^ORCID,Dari Silvia³,Clarke Christopher⁴,Curran Desmond⁴^ORCID,Loiacono Idalba⁵,Pitrelli Andrea⁵,Puggina Anna⁵,Tosatto Roberta⁵,Van Oorschot Desirée⁴,Franco Elisabetta⁶^ORCID

Affiliation:

1. Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, Italy

2. Department of Health Sciences, University of Florence, Florence, Italy

3. NEOS (Neuroscienze, Salute Mentale e Organi di Senso), Sapienza University, Rome, Italy

4. Health Economics Zoster, GSK, Wavre, Belgium

5. ITA Market Access and Pricing, GSK Italy, Verona, Italy

6. Department of Biomedicine and Prevention, University “Tor Vergata”, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2019.1657753

Reference39 articles.

1. Herpes zoster and postherpetic neuralgia

2. Herpes Zoster

3. Varicella-zoster virus

4. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data

5. Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain;Human Vaccines & Immunotherapeutics;2024-06-26

2. Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK;Infectious Diseases and Therapy;2024-04-24

3. Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy;Vaccines;2024-04-19

4. Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older;PharmacoEconomics - Open;2024-04-11

5. Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia;Infectious Diseases and Therapy;2024-03-17